ASCO 2022 Conference Coverage


 

ASCO 2022 on PROOF 301 Trial: Updates on Infigratinib vs. Gemcitabine + Cisplatin in Advanced Cholangiocarcinoma With a FGFR2 Gene Fusion/Rearrangement

1,149 views
June 7, 2022
Comments 1
Login to view comments. Click here to Login